Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Dec 3;9(12):1156-1159.
doi: 10.1021/acsmedchemlett.8b00566. eCollection 2018 Dec 13.

Recent Advances and Perspectives in Small-molecule TLR Ligands and Their Modulators

Nikunj M Shukla  1 , Michael Chan  1 , Tomoko Hayashi  1 , Dennis A Carson  1 , Howard B Cottam  1
Affiliations
Editorial

Recent Advances and Perspectives in Small-molecule TLR Ligands and Their Modulators

Nikunj M Shukla et al. ACS Med Chem Lett. .

Abstract

Activation of Toll-like receptors (TLRs) located on immune cells leads to induction of immune responses that can be useful in vaccines for infectious diseases, cancer immunotherapy, and autoimmune diseases. Novel TLR signaling pathway modulators can further enhance the efficacy of TLR ligands.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Structures of selected small-molecule TLR agonists. TLR2 agonists shown in red, TLR4 in blue, and TLR7/8 in green.
Figure 2
Figure 2
Theoretical kinetic profiles for immune stimulation.
See this image and copyright information in PMC

References

    1. Zhu G.; Xu Y.; Cen X.; Nandakumar K. S.; Liu S.; Cheng K. Targeting pattern-recognition receptors to discover new small molecule immune modulators. Eur. J. Med. Chem. 2018, 144, 82–92. 10.1016/j.ejmech.2017.12.026. - DOI - PubMed
    1. Kang J. Y.; Nan X.; Jin M. S.; Youn S. J.; Ryu Y. H.; Mah S.; Han S. H.; Lee H.; Paik S. G.; Lee J. O. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 2009, 31 (6), 873–84. 10.1016/j.immuni.2009.09.018. - DOI - PubMed
    1. Chan M.; Kakitsubata Y.; Hayashi T.; Ahmadi A.; Yao S.; Shukla N. M.; Oyama S. Y.; Baba A.; Nguyen B.; Corr M.; Suda Y.; Carson D. A.; Cottam H. B.; Wakao M. Structure-activity relationship studies of pyrimido[5,4-b]indoles as selective Toll-like receptor 4 ligands. J. Med. Chem. 2017, 60 (22), 9142–9161. 10.1021/acs.jmedchem.7b00797. - DOI - PMC - PubMed
    1. Wang Y.; Su L.; Morin M. D.; Jones B. T.; Whitby L. R.; Surakattula M. M.; Huang H.; Shi H.; Choi J. H.; Wang K. W.; Moresco E. M.; Berger M.; Zhan X.; Zhang H.; Boger D. L.; Beutler B. TLR4/MD-2 activation by a synthetic agonist with no similarity to LPS. Proc. Natl. Acad. Sci. U. S. A. 2016, 113 (7), E884–93. 10.1073/pnas.1525639113. - DOI - PMC - PubMed
    1. Lee J.; Chuang T. H.; Redecke V.; She L.; Pitha P. M.; Carson D. A.; Raz E.; Cottam H. B. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc. Natl. Acad. Sci. U. S. A. 2003, 100 (11), 6646–51. 10.1073/pnas.0631696100. - DOI - PMC - PubMed

Publication types